Which ASX-listed companies are exempt from the U.S. pharmaceutical tariffs?

Companies like Mesoblast Limited (ASX:MSB) and Telix Pharmaceuticals Limited (ASX:TLX), with U.S.-based manufacturing, are exempt due to their "U.S. origin" product designation.

How can investors assess the impact of the new tariffs on ASX healthcare stocks?

Investors should evaluate companies' exposure to the U.S. market, their manufacturing locations, and any statements or guidance provided by the companies regarding the tariff's impact.

What legal avenues exist to challenge the new U.S. pharmaceutical tariffs?

Affected parties may pursue legal challenges through international trade agreements, such as the World Trade Organization, to contest the tariff's application and seek exemptions.

Navigating the Storm: How Trump's Pharma Tariffs Impact ASX Healthcare Stocks

4 min read | September 29, 2025 10:46 PM AEST | By Sam

Google News:

Navigating the Storm: How Trump's Pharma Tariffs Impact ASX Healthcare Stocks — Image source: Shutterstock

What Are the Key Details of Trump's Pharma Tariff?

The new tariff mandates that imported branded and patented medicines face a 100% levy unless the manufacturing company is actively constructing a production facility in the U.S. This policy aims to bolster domestic manufacturing but has raised concerns about increased drug prices and potential shortages.

Which ASX-Listed Companies Are Most Affected?

CSL Limited (ASX:CSL)

CSL Limited, a global biotechnology company, has significant operations in the U.S., including plasma collection and vaccine manufacturing. Despite the tariff, CSL has reaffirmed its FY26 guidance, suggesting minimal direct impact. However, market reactions have included a decline in share value, reflecting investor concerns.

Mesoblast Limited (ASX:MSB)

Mesoblast specializes in allogeneic cellular medicines. The company has clarified that its products are manufactured from U.S. donors in U.S. facilities, designating them as U.S. origin and exempt from the new tariffs. This strategic positioning provides Mesoblast with a competitive advantage in the face of the tariff.

Telix Pharmaceuticals Limited (ASX:TLX)

Telix Pharmaceuticals, focused on molecularly targeted radiation, has extensive U.S.-based manufacturing and distribution infrastructure. The company has stated that it does not expect any material impact from the new tariffs, leveraging its domestic operations to mitigate potential disruptions.

Pro Medicus Limited (ASX:PME)

Pro Medicus, a provider of medical imaging software, does not manufacture pharmaceuticals and thus is not subject to the new tariffs. The company's operations remain unaffected, allowing it to continue its growth trajectory without the burden of tariff-related challenges.

Cochlear Limited (ASX:COH)

Cochlear specializes in implantable hearing solutions. While the new tariffs primarily target pharmaceuticals, Cochlear has sought clarification on the application of the tariff to its products. The company is closely monitoring the situation to assess any potential impacts on its operations.

How Are Investors Reacting to the Tariff Announcement?

Investor reactions have been mixed, with some healthcare stocks experiencing declines due to the uncertainty surrounding the new tariffs. However, companies with established U.S. operations, like CSL, Telix, and Mesoblast, have shown resilience, indicating that strategic positioning in the U.S. market can mitigate some of the adverse effects of the tariff.

What Legal and Regulatory Challenges Could Arise?

The imposition of a 100% tariff on pharmaceuticals may face legal challenges, particularly from international trade associations and affected countries. Disputes may arise concerning the interpretation of "under construction" for manufacturing facilities and the applicability of the tariff to various pharmaceutical products. These challenges could lead to exemptions or modifications to the tariff policy.

How Are ASX 200 Healthcare Stocks Performing?

Despite initial market volatility following the tariff announcement, the ASX 200 has shown resilience, with certain healthcare stocks rebounding as investors reassess the potential impacts. Companies with diversified operations and strong U.S. presences are leading this recovery, highlighting the importance of strategic global positioning.

What Should Investors Consider Moving Forward?

Investors should closely monitor the developments surrounding the U.S. pharmaceutical tariff, paying particular attention to the legal challenges and potential exemptions that may arise. Companies with significant U.S. operations and those in the process of establishing domestic manufacturing facilities are better positioned to navigate the impacts of the tariff. Diversification within the healthcare sector can also provide a buffer against sector-specific risks.

Frequently Asked Questions

Which ASX-listed companies are exempt from the U.S. pharmaceutical tariffs?

Companies like Mesoblast Limited (ASX:MSB) and Telix Pharmaceuticals Limited (ASX:TLX), with U.S.-based manufacturing, are exempt due to their "U.S. origin" product designation.
How can investors assess the impact of the new tariffs on ASX healthcare stocks?

Investors should evaluate companies' exposure to the U.S. market, their manufacturing locations, and any statements or guidance provided by the companies regarding the tariff's impact.
What legal avenues exist to challenge the new U.S. pharmaceutical tariffs?

Affected parties may pursue legal challenges through international trade agreements, such as the World Trade Organization, to contest the tariff's application and seek exemptions.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.